Gilead Sciences
Open
$125.25
Prev. Close
$125.29
High
$125.63
Low
$125.25
Market Snapshot
$155.91B
16.9
0.37
$28.75B
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The company operates in over 35 countries worldwide.
Gilead Sciences donated remdesivir to Uganda to support efforts against the Ebola outbreak, reinforcing its commitment to global health initiatives and infectious disease response.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The company operates in over 35 countries worldwide.
Recently from Cashu
Gilead Sciences Ends Lung Cancer Trial with Merck Amidst Disappointing Efficacy Results
Gilead Sciences (Ticker: GILD) concludes a clinical trial partnership with Merck & Co. focusing on lung cancer treatments. The trial evaluates the effects of combining Trodelvy with Keytruda, aiming t…
Gilead Sciences Expands Autoimmune Portfolio with Acquisition of Ouro Medicines and Gamgertamig
Gilead Sciences has successfully completed the acquisition of Ouro Medicines, marking a significant step in its strategy to expand its portfolio in the autoimmune disease sector. This acquisition intr…
Gilead Sciences Secures FDA Approvals for Hepcludex and Livdelzi, Enhancing Specialty Disease Portfolio
Gilead Sciences (Ticker: GILD) achieves major regulatory milestones that enhance its pharmaceutical portfolio, particularly within specialty diseases. A landmark moment arrives with the U.S. Food and…
Gilead Sciences Expands Oncology and Inflammation Focus, Enhances Growth Strategy at Healthcare Conference
Gilead Sciences (Ticker: GILD) is making significant strides in its operational strategy, focusing on expanding its therapeutic areas beyond HIV, which has been its cornerstone. At the recent Bank of…